Is Vertex Pharmaceuticals Stock a Good Investment?

Vertex Pharmaceuticals Investment Advice

  VRTX
To provide specific investment advice or recommendations on Vertex Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Vertex Pharmaceuticals. This will help you to make an informed decision on whether to include Vertex Pharmaceuticals in one of your diversified portfolios:
  • Examine Vertex Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Vertex Pharmaceuticals' leadership team and their track record. Good management can help Vertex Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Vertex Pharmaceuticals' business and its evolving consumer preferences.
  • Compare Vertex Pharmaceuticals' performance and market position to its competitors. Analyze how Vertex Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
  • Check if Vertex Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Vertex Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vertex Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vertex Pharmaceuticals is a good investment.
 
Sell
 
Buy
Strong Sell
Macroaxis provides recommendation on Vertex Pharmaceuticals to complement and cross-verify current analyst consensus on Vertex Pharmaceuticals. Our trade recommendation engine determines the firm's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Vertex Pharmaceuticals is not overpriced, please validate all Vertex Pharmaceuticals fundamentals, including its total debt, earnings per share, and the relationship between the net income and book value per share . Given that Vertex Pharmaceuticals has a price to earning of 24.57 X, we advise you to double-check Vertex Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Market Performance

Very WeakDetails

Volatility

Very steadyDetails

Hype Condition

StaleDetails

Current Valuation

Fairly ValuedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Reporting Quality (M-Score)

UnavailableDetails

Examine Vertex Pharmaceuticals Stock

Researching Vertex Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.54. Vertex Pharmaceuticals recorded earning per share (EPS) of 13.89. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000.
To determine if Vertex Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vertex Pharmaceuticals' research are outlined below:
Vertex Pharmaceuticals generated a negative expected return over the last 90 days
Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from investing.com: Vertex Energy director Odeh Khoury sells 2,610 in stock

Vertex Pharmaceuticals Quarterly Good Will

1.09 Billion

Vertex Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vertex Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vertex Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vertex Pharmaceuticals' investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-01-29
2012-12-31-0.08-0.09-0.0112 
2016-10-25
2016-09-300.180.16-0.0211 
2000-02-16
1999-12-310.010.030.02200 
1999-07-27
1999-06-30-0.19-0.21-0.0210 
1998-02-23
1997-12-31-0.15-0.130.0213 
1997-04-22
1997-03-31-0.15-0.130.0213 
2016-07-27
2016-06-300.210.240.0314 
1999-10-27
1999-09-30-0.25-0.28-0.0312 

Know Vertex Pharmaceuticals' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Massachusetts Financial Services Company2023-12-31
3.6 M
Capital Research Global Investors2023-12-31
3.6 M
Loomis, Sayles & Company Lp2023-12-31
3.1 M
Norges Bank2023-12-31
M
Morgan Stanley - Brokerage Accounts2023-12-31
M
Goldman Sachs Group Inc2023-12-31
M
Amundi2023-12-31
2.7 M
Northern Trust Corp2023-12-31
2.7 M
Ubs Asset Mgmt Americas Inc2023-12-31
2.6 M
Vanguard Group Inc2023-12-31
22.3 M
Blackrock Inc2023-12-31
21.9 M
Note, although Vertex Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Pharmaceuticals' market capitalization trends

The company currently falls under 'Mega-Cap' category with a current market capitalization of 103.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Market Cap

8.37 Billion

Vertex Pharmaceuticals' profitablity analysis

Vertex Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Vertex Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Vertex Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vertex Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vertex Pharmaceuticals' profitability requires more research than a typical breakdown of Vertex Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.17  0.18 
Return On Capital Employed 0.20  0.21 
Return On Assets 0.16  0.17 
Return On Equity 0.21  0.22 
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.
Determining Vertex Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Vertex Pharmaceuticals is a good buy. For example, gross profit margin measures Vertex Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vertex Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Vertex Pharmaceuticals' official financial statements usually reflect Vertex Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vertex Pharmaceuticals. For example, before you start analyzing numbers published by Vertex accountants, it's critical to develop an understanding of what Vertex Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Vertex Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.

Evaluate Vertex Pharmaceuticals' management efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.
Last ReportedProjected for Next Year
Book Value Per Share 68.22  71.63 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 60.74  63.78 
Enterprise Value Over EBITDA 24.24  23.03 
Price Book Value Ratio 5.96  7.46 
Enterprise Value Multiple 24.24  23.03 
Price Fair Value 5.96  7.46 
Enterprise Value15.8 B8.3 B
The analysis of Vertex Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vertex Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vertex Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.368

Basic technical analysis of Vertex Stock

As of the 13th of April 2024, Vertex Pharmaceuticals has the Risk Adjusted Performance of (0.03), coefficient of variation of (1,934), and Variance of 1.47. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Vertex Pharmaceuticals, which can be compared to its competition. Please validate Vertex Pharmaceuticals standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if Vertex Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 396.55 per share. Given that Vertex Pharmaceuticals has information ratio of (0.12), we advise you to double-check Vertex Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Vertex Pharmaceuticals' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Understand Vertex Pharmaceuticals' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Vertex Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Vertex Pharmaceuticals' intraday indicators

Vertex Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vertex Pharmaceuticals Corporate Filings

8K
11th of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
10th of April 2024
An amended filing to the original Schedule 13G
ViewVerify
4th of April 2024
Other Reports
ViewVerify
F4
3rd of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
Vertex Pharmaceuticals time-series forecasting models is one of many Vertex Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Vertex Stock media impact

Far too much social signal, news, headlines, and media speculation about Vertex Pharmaceuticals that are available to investors today. That information is available publicly through Vertex media outlets and privately through word of mouth or via Vertex internal channels. However, regardless of the origin, that massive amount of Vertex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vertex Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vertex Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vertex Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vertex Pharmaceuticals alpha.

Vertex Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Vertex Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Vertex Pharmaceuticals Historical Investor Sentiment

Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Vertex Pharmaceuticals.

Vertex Pharmaceuticals Maximum Pain Price across 2024-04-19 Option Contracts

Vertex Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Vertex Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Vertex Pharmaceuticals' options.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Vertex Pharmaceuticals Corporate Directors

Vertex Pharmaceuticals corporate directors refer to members of a Vertex Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Vertex Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vertex Pharmaceuticals' board members must vote for the resolution. The Vertex Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
William YoungIndependent DirectorProfile
Alan GarberIndependent DirectorProfile
Margaret McGlynnIndependent DirectorProfile
Sangeeta BhatiaDirectorProfile

How to buy Vertex Stock?

To provide specific investment advice or recommendations on Vertex Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Vertex Pharmaceuticals. This will help you to make an informed decision on whether to include Vertex Pharmaceuticals in one of your diversified portfolios:
  • Examine Vertex Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Vertex Pharmaceuticals' leadership team and their track record. Good management can help Vertex Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Vertex Pharmaceuticals' business and its evolving consumer preferences.
  • Compare Vertex Pharmaceuticals' performance and market position to its competitors. Analyze how Vertex Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
  • Check if Vertex Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Vertex Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vertex Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vertex Pharmaceuticals is a good investment.

Already Invested in Vertex Pharmaceuticals?

The danger of trading Vertex Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vertex Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vertex Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vertex Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.89
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Vertex Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.